SC
KROS icon

SummitTX Capital’s Keros Therapeutics KROS Stock Holding History

SummitTX Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-40,000
Closed -$633K – 848
2025
Q3 		$633K Hold
40,000
– – 0.03% 474
2025
Q2 		$534K Buy
40,000
+9,116
+30% +$123K 0.02% 499
2025
Q1 		$315K Buy
+30,884
New +$359K 0.01% 650

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SummitTX Capital's KROS Position: Q4 2025 in Review

SummitTX Capital sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 40,000 shares — an estimated $633K sold.

SummitTX Capital first reported a position in KROS in Q1 2025 and held it in 3 quarters. The position peaked at $633K in Q3 2025. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • SummitTX Capital reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SummitTX Capital sold 40,000 Keros Therapeutics shares in Q4 2025, an estimated $633K.
  • SummitTX Capital first reported a position in Keros Therapeutics in Q1 2025 and held it in 3 quarters.
  • SummitTX Capital's Keros Therapeutics position peaked at $633K in Q3 2025.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.